Maurice Hilleman, 85, Created Many Critical Vaccines

This article is from the archive of The New York Sun before the launch of its new website in 2022. The Sun has neither altered nor updated such articles but will seek to correct any errors, mis-categorizations or other problems introduced during transfer.

The New York Sun

Maurice Hilleman, a pioneer in vaccine research who developed vaccines for mumps, measles, chicken pox and other childhood scourges, died yesterday of cancer. He was 85.


Hilleman worked for Whitehouse Station-based Merck & Co. Inc. for nearly 30 years before retiring in 1984.


Over his career, the Montana native led or began the development of vaccines against diseases that once killed or hospitalized millions, including measles, German measles, meningitis, pneumonia and hepatitis A and B. He began work on the mumps vaccine after his daughter, Jeryl Lynn, developed the illness at age 5 in 1963.


“Maurice Hilleman will be historically remembered as the vaccinologist of the 20th century,” Dr. Robert C. Gallo, director of the Institute of Human Virology at University of Maryland, said in a prepared statement. “His name will be joined forever with people like Pasteur and Koch in the story of man’s strivings against pathogens.”


Hilleman joined Merck in 1957 as head of its new virus and cell biology research department, after a decade as chief of respiratory diseases at Walter Reed Army Institute of Research.


“His work has saved literally millions of lives and has protected many millions more from disease,” said Dr. Adel F. Mahmoud, president of Merck Vaccines.


He was awarded the National Medal of Science by President Ronald Reagan in July 1988.


The New York Sun

© 2025 The New York Sun Company, LLC. All rights reserved.

Use of this site constitutes acceptance of our Terms of Use and Privacy Policy. The material on this site is protected by copyright law and may not be reproduced, distributed, transmitted, cached or otherwise used.

The New York Sun

Sign in or  create a free account

or
By continuing you agree to our Privacy Policy and Terms of Use